AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy of Dermatology and Venereology Congress

NORTH CHICAGO Ill. Sept. 26 2016 PRNewswire &160;AbbVie NYSE ABBV a global biopharmaceutical company today announced that new data on HUMIRA&174; adalimumab and investigational medicine risankizumab formerly BI 655066 an IL23 inhibitor will be pres...